

## Indoco's Net Revenues Up by 6.2 %

**Mumbai, January 27, 2017:** Indoco Remedies posted total revenues of ₹ 272.2 crores for the third quarter of Oct 16-Dec16, up by 6.2 %, as against ₹ 256.4 crores for the same period last year. Profit After Tax (PAT) for the quarter was at ₹ 17.6 crores compared to ₹ 19.00 crores for the corresponding quarter last year.

**Commenting on this development, Aditi Panandikar, Managing Director, Indoco Remedies Ltd, said,** *“The Indian Pharma Industry was impacted due to demonetization and the pressure was felt more in acute therapies. However, the normalcy is getting restored and our sales will see growth rates in the coming quarters”.*

The Company's domestic formulation business introduced 9 new products, three in Anti-Diabetic, three in Respiratory and three in Stomatologicals.

For the quarter ended Dec'16, the financials are as under:

(₹ in Crores)

| Particulars  | Oct'16 – Dec'16 | Oct'15 – Dec'15 |
|--|-----------------|-----------------|
| <b>Net Revenue</b>                                 | 272.2           | 256.4           |
| <b>EBIDTA</b>                                      | 39.5            | 42.8            |
| <b>Profit After Tax</b>                            | 17.6            | 19.00           |
| <b>EPS (Face value ₹ 2/-)<br/>(Not annualized)</b> | 1.91            | 2.06            |

### **About Indoco Remedies Limited:**

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 149 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 67

million prescriptions annually from around 2,10,000 doctors in India. Indoco has 10 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Tuspel Plus, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

**For Media Inquiries Please Contact:**

**Vilas V. Nagare**

Mobile: 9820215745

E-mail: [vilasn@indoco.com](mailto:vilasn@indoco.com)